Research & Development

Can Merck and SCRI Bridge the Gap in Oncology Trials?
Research & Development Can Merck and SCRI Bridge the Gap in Oncology Trials?

The strategic alliance between Merck and the Sarah Cannon Research Institute aims to transform oncology research by deploying a network of over 200 locations and 1,500 oncology physicians. This massive undertaking addresses a fundamental imbalance in modern medicine: while nearly eighty-five

Japan Approves Sevabertinib for HER2-Mutant Lung Cancer
Research & Development Japan Approves Sevabertinib for HER2-Mutant Lung Cancer

The SOHO-01 trial results highlight that gastrointestinal and skin-related issues such as diarrhea and rash are the most common side effects, which are generally considered manageable by clinicians. On August 24, 2026, Japan’s Ministry of Health, Labour and Welfare reached a landmark decision by

FDA Issues Second Hold on Regenxbio Hunter Syndrome Therapy
Research & Development FDA Issues Second Hold on Regenxbio Hunter Syndrome Therapy

Sponsors of CNS-directed gene therapies are now being urged to embed independent imaging review boards directly into their trial protocols to avoid similar regulatory failures. This directive follows the U.S. Food and Drug Administration's decision to issue a second clinical hold on Regenxbio’s

Can New Treatments Replace Rectal Cancer Surgery?
Research & Development Can New Treatments Replace Rectal Cancer Surgery?

International researchers have identified a five-week chemoradiotherapy protocol that allows four out of five patients to avoid major surgery while maintaining their quality of life. This paradigm shift in oncology marks a departure from the traditional approach, where radical excision was

Safe Stem Cell Transplant Methods for Cold Agglutinin Disease
Research & Development Safe Stem Cell Transplant Methods for Cold Agglutinin Disease

Standard laboratory protocols for washing and preparing harvested stem cells must be modified with pre-warmed solutions to prevent thermal shock in sensitive biological samples. This requirement becomes critically apparent when treating patients with Cold Agglutinin Disease (CAD), a rare autoimmune

Glioma Microenvironment Modulation – Review
Research & Development Glioma Microenvironment Modulation – Review

The persistent failure of conventional neuro-oncology treatments to extend median survival beyond eighteen months has catalyzed a profound transition from targeting individual malignant cells to orchestrating the total disruption of the glioma microenvironment. This shift represents more than just

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later